ClinicalTrials.gg
CompletedNCT03425552Updated Jul 19, 2019

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

A Phase 1/2 interventional study of Paliperidone and Paliperidone in Schizophrenia, sponsored by Pharmathen S.A.. Completed at 3 sites in Jordan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-19.

Sponsored by Pharmathen S.A. · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
83rd of 115
70 · median 178
Started
2018
with 1 other
Phase 1/2
Only one
of the 115
Registered
100th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 83rd largest by enrollment, is one of 2 that started in 2018, is the only one in phase 1/2, and was the 100th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this treatment. Each patient will receive both products (Test and Reference). In total, each patient will receive 10 doses (five doses of the Test product and five doses of the Reference product; one dose every 28 days). Furthermore, the two products (Test and Reference) will be compared with regard to their safety and tolerability.

Read the detailed description

This study will be a randomized, two-way, two-treatment, two-period, crossover, open label, laboratory-blind, multiple dose study at steady state, under fasting conditions.

To main purpose of this study is to determine the relative bioavailability of Paliperidone 100 mg prolonged release suspension for injection (Pharmathen S.A, Greece) and Xeplion® (Paliperidone) 100 mg Prolonged Release Suspension for Injection (Janssen Pharmaceutica N.V., Belgium) following multiple Intramuscular Injections (five doses in each period, one dose every 28 days) administration to patients with schizophrenia who are already receiving a stable regimen of paliperidone prolonged release suspension via the intramuscular route.

The secondary objective of this study is to evaluate the safety and tolerability between the two products.

Five injections of Paliperidone 100 mg prolonged release suspension will be administered intramuscularly (in the deltoid muscle) to study patients in each period (one injection every 28 days).

A total of 70 patients will be randomized into two sequences (Test-Reference or Reference-Test).

The doses will be administered to study patients in each period, according to the randomization plan , as clarified in the table below:

Period I Day 0 First dose Day 28 Second dose Day 56 Third dose Day 84 Fourth dose Day 112 Fifth Dose

Period II Day 140 First dose Day 168 Second dose Day 196 Third dose Day 224 Fourth dose Day 252 Fifth Dose

Following up the last dose of each period, a series of blood samples will be collected from each patient in order to determine the bioavailability of the received drug. More specifically, patients will return to the clinical site to give the scheduled PK blood samples on Day 113, Day114, Day 115, Day 116, Day 117, Day 118, Day 119, Day 120, Day 121, Day 122, Day 123, Day 124, Day 125, Day 126, Day 127, Day 128, Day 129, Day 130, Day 132, Day 134, Day 136, Day 138, Day 253, Day 254, Day 255, Day 256, Day 257, Day 258, Day 259, Day 260, Day 261, Day 262, Day 263, Day 264, Day 265, Day 266, Day 267, Day 268, Day 269, Day 270, Day 272, Day 274, Day 276, Day 278 and Day 280.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is suffering from Schizophrenia.
  • The patient age is > 18 years and \< 65 years old (inclusive).
  • The patient has a body weight not less than 50 Kg and according to the range (18.5 - 35 Kg/m2), (inclusive)
  • The patient has received at least 3 doses of Paliperidone 100 mg Prolonged Release Suspension for Injection within the last 3 months.
  • The patient is under fasting conditions (food and drinks) for at least 8 hours on the day of screening.
  • The patient is available to volunteer for the entire study duration and is willing to adhere to all protocol requirements.
  • The findings of the patient are within the range of clinical acceptability in medical history, physical examination, vital signs, , and laboratory results.
  • The legally acceptable representative signed the form and the patient is able to communicate with the investigator and comprehend study-related procedures.
  • The patient agrees to use a condom if he is engaged in sexual activity with a woman of .

A condom is required along with another medically acceptable method. Medically acceptable methods of contraception include non-hormonal intrauterine device or double barrier method (condom with foam or vaginal spermicidal suppository, diaphragm with spermicide).

  • Female patients may be included but must comply with the following in order to be included:
  • Women having the potential to become pregnant can be enrolled only if willing to use a clinically acceptable (i.e. intrauterine device or hormonal contraceptives for at least three months) or a double barrier contraceptive measure (i.e. condom and spermicidal gel or diaphragm and spermicidal gel for at least 14 days) prior to the start of the study and through the study and for 30 days after completion of the study, or
  • Surgically sterilized for at least 6 months or
  • Menopausal women, for at least 1 year

Exclusion criteria

Exclusion Criteria:

  • The patient is pregnant or nursing (lactating) women, where pregnancy is defined as the state of the female after conception and until the termination of gestation, confirmed by a positive urine or serum pregnancy test.
  • The patient has any significant or organ abnormality as determined by the principal investigator/sub-investigator.
  • The patient has skin abnormalities/irritations at the potential injection site (right or left deltoid) as determined by the Principal Investigator/clinical Sub-Investigator.
  • The patient has a medical or surgical condition that might interfere with the absorption, metabolism, or excretion of paliperidone.
  • The patient has known allergy to the Paliperidone Palmitate or to any ingredient in the preparation.
  • The patient has a history of to heparin.
  • The patient intended to significantly change the smoking habits during the trial (i.e. planned cessation or start of smoking career).
  • The patient will consume alcohol or caffeine or related xanthine containing foods or beverages for 48 hours prior to each dosing.
  • The patient will consume grapefruit or pomelo-containing beverages and foods within 7 days prior to each dosing.
  • The patient has a history of or current compulsive abuse of alcohol (more than 10 drinks weekly) or regular exposure to other substance of abuse.
  • The patient is on a special diet (for example the patient is a vegetarian), or dieting (on a weight lowering plan) during the month before the study.
  • The patient participated in a comparative bioavailability/ bioequivalence study within the last 90 days before first dose of period I.
  • The patient participated in a clinical study within the last 90 days before first dose of period I.
  • The patient donated blood or any of its constituents (1 unit or 350 ml) within the last 90 days before first dose of period I.
  • The patient has positive testing for I \& II and/or and/or using ELISA method.
  • The patient has positive test for illicit drugs or alcohol before any dose.
  • The patient is suffering from severe hepatic impairment.
  • The patient is suffering from renal impairment
  • Presence or history of cardiovascular disease (especially known history of , congenital long QT syndrome, recent acute myocardial infarction, cardiac arrhythmias, or with uncompensated heart failure).
  • The patient is receiving medicinal products known to prolong the QT interval, e.g. class 1 Antiarrhythmics (e.g., quinidine, disopyramide, procainamide) and class III antiarrhythmics (e.g. amiodarone, sotalol), antihistamines, antipsychotics known to prolong QT interval, and antimalarials (e.g. mefloquine, quinine), tricyclic antidepressants (eg amitriptyline), tetracyclic antidepressants (eg maprotiline).
  • The patient is receiving centrally acting medicinal products e.g. anxiolytics, risperidone, opiates, etc. or alcohol
  • The patient is receiving drugs that induce orthostatic hypotension (e,g other antipsychotics, tricyclic).
  • The patient is receiving medicinal products known to lower the seizure threshold (e.g. phenothiazines or butyrophenones, tricyclics or SSRIs, tramadol, mefloquine, etc.)
  • The patient is receiving carbamazepine (causes decrease in mean steady state Cmax and AUC of Paliperidone)
  • The patient has current thoughts of suicide or violent tendencies at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Test treatment

    Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)

    Drug: Paliperidone

  • Active comparator
    Reference treatment

    Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension

    Drug: Paliperidone

Interventions

  • Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)

  • Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension

    Also known as: Xeplion

06

What researchers measure

Primary outcomes

  1. Cmax(ss)

    Maximum plasma concentration at steady state

    Time frame: 28 days

  2. AUC0-τ(ss)

    AUC during a dosage interval at steady state

    Time frame: 28 days

  3. Cτ(ss)

    Concentration at the end of the dosing interval at steady state

    Time frame: 28 days

Secondary outcomes

  1. Cmin(ss)

    Minimum plasma concentration at steady state

    Time frame: 28 days

  2. Fluctuation

    (Cmax,ss - Cmin,ss) / Cavg,ss

    Time frame: 28 days

  3. Tmax(ss)

    Time until Cmax(ss) is reached

    Time frame: 28 days

  4. Number of participants with treatment-related adverse events

    Time frame: 281 days

07

Study locations

3 sites
  • Al-Esraa Hospital
    Amman, Jordan
  • King Abdullah University Hospital
    Ar Ramtha, Jordan
  • Princes Basma Teaching Hospital
    Irbid, Jordan
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in May 2019, 13 months.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 7, 2018
StartActual
Mar 11, 2018
Primary completionActual
May 2, 2019
CompletionActual
May 2, 2019
Last update
Jul 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03425552
Lead sponsor
Pharmathen S.A.
Responsible party
Sponsor
First posted
Feb 7, 2018
Start date
Mar 11, 2018
Primary completion
May 2, 2019
Completion
May 2, 2019
Last update
Jul 19, 2019

Study contacts

Lina Sabbah
study director · Triumpharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion